QUOTE AND NEWS
Reuters  3 hrs ago  Comment 
Mylan Sees q2 adjusted eps $0.86 to $0.90
Reuters  4 hrs ago  Comment 
Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co and believes it...
newratings.com  May 5  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
Motley Fool  May 3  Comment 
Teva Pharmaceuticals, Mylan Inc., and Perrigo can't seem to agree on how much generic-drug companies are worth.
newratings.com  May 1  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
The Economist  Apr 30  Comment 
THE plot is worthy of a Shakespearean comedy. Teva is in pursuit of Mylan. But Mylan dislikes its suitor and runs away to declare its love for Perrigo, while seeking a poison pill in case it is forced to marry Teva. Perrigo, though, rebuffs Mylan....
newratings.com  Apr 30  Comment 
Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, ...
New York Times  Apr 30  Comment 
Seeking to fend off an unwanted bid from Teva, Mylan increased its cash-and-stock offer for Perrigo.
New York Times  Apr 29  Comment 
Seeking to fend off an unwanted bid from Teva, Mylan increased its cash-and-stock offer for Perrigo.
newratings.com  Apr 29  Comment 
FiercePharma  Apr 27  Comment 
On Friday, Mylan all but rejected Teva's takeover bid with its own sweetened bid for Ireland's Perrigo. But now, it's made the snub official, delivering a resounding "no" to its generics rival.




 

Perrigo Company is a global health-care supplier and the world's largest manufacturer of over-the-counter pharmaceuticals for the store brand market. The company develops, distributes, and manufactures over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and consumer products.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki